Author:
Zhong Xiaoyan,Lai Dan,Ye Yun,Yang Xuping,Yu Bin,Huang Yilan
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference37 articles.
1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149
2. Action to control cardiovascular risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559
3. European Medicines Agency (EMA). EMEA/H/C/002677. Jardiance. EPAR. Product information. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf . Accessed 18 June 2014
4. U.S. Food and Drug Administration. Jardiance® (empagliflozin) tablets, for oral use. Initial U.S. Approval: 2014 [prescribing information]. Ingelheim, Germany: Boehringer Ingelheim; 2014. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf . Accessed 8 August 2014
5. DeFronzo RA, Davidson JA, Del Prato S (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14(1):5–14
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献